Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib maintenance therapy in primary central nervous system lymphoma
ChiCTR2200065917Phase 2Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of zanubrutinib in primary central nervous system lymphoma (PCNSL) (2 arms), sponsored by Huashan Hospital. Primary endpoint: Progression-free survival. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
zanubrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on ChiCTR2200065917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065917.